Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia : when to change? A perspective in 2009MAURO, Michael J.Current opinion in hematology. 2009, Vol 16, Num 2, pp 135-139, issn 1065-6251, 5 p.Article

Transplantation for chronic myelogenous leukemia: yes, no, maybe so... an Oregon perspectiveMAZIARZ, Richard T; MAURO, Michael J.Bone marrow transplantation (Basingstoke). 2003, Vol 32, Num 5, pp 459-469, issn 0268-3369, 11 p.Article

Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaPINILLA-LBARZ, Javier; CORTES, Jorge; MAURO, Michael J et al.Cancer. 2011, Vol 117, Num 4, pp 688-697, issn 0008-543X, 10 p.Article

Stem cell transplantation in patients with chronic myelogenous leukemia : When should it be used?MAURO, Michael J; MAZIARZ, Richard T.Mayo Clinic proceedings. 2006, Vol 81, Num 3, pp 404-416, issn 0025-6196, 13 p.Article

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studySHAH, Neil P; TALPAZ, Moshe; HALUSKA, Frank G et al.British journal of haematology. 2013, Vol 162, Num 4, pp 548-552, issn 0007-1048, 5 p.Article

Ponatinib in Refractory Philadelphia Chromosome: Positive LeukemiasCORTES, Jorge E; KANTARJIAN, Hagop; CLACKSON, Tim et al.The New England journal of medicine. 2012, Vol 367, Num 22, pp 2075-2088, issn 0028-4793, 14 p.Article

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CMLO'DWYER, Michael E; MAURO, Michael J; KURILIK, Gwen et al.Blood. 2002, Vol 100, Num 5, pp 1628-1633, issn 0006-4971, 6 p.Article

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia : validating the promise of molecularly targeted therapyMAURO, Michael J; O'DWYER, Michael E; DRUKER, Brian J et al.Cancer chemotherapy and pharmacology. 2001, Vol 48, pp S77-S78, issn 0344-5704, SUP1Conference Paper

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesSONNICHSEN, Daryl; DORER, David J; LITWIN, Jeffrey et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 6, pp 1599-1607, issn 0344-5704, 9 p.Article

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasEMMANUEL NICOLINI, Franck; BASAK, Grzegorz W; SAGLIO, Giuseppe et al.Blood. 2011, Vol 118, Num 20, pp 5697-5700, issn 0006-4971, 4 p.Article

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylateO'DWYER, Michael E; MAURO, Michael J; BLASDEL, Carolyn et al.Blood. 2004, Vol 103, Num 2, pp 451-455, issn 0006-4971, 5 p.Article

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experienceBRAZIEL, Rita M; LAUNDER, Teresa M; DRUKER, Brian J et al.Blood. 2002, Vol 100, Num 2, pp 435-441, issn 0006-4971Article

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibPRESS, Richard D; WILLIS, Stephanie G; LAUDADIO, Jennifer et al.Blood. 2009, Vol 114, Num 13, pp 2598-2605, issn 0006-4971, 8 p.Article

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CMLPRESS, Richard D; LOVE, Zac; TRONNES, Ashlie A et al.Blood. 2006, Vol 107, Num 11, pp 4250-4256, issn 0006-4971, 7 p.Article

Chronic myeloid leukemia : Current application of cytogenetics and molecular testing for diagnosis and treatmentTEFFERI, Ayalew; DEWALD, Gordon W; LITZOW, Mark L et al.Mayo Clinic proceedings. 2005, Vol 80, Num 3, pp 390-402, issn 0025-6196, 13 p.Article

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-lnduced complete cytogenetic responsePRESS, Richard D; GALDERISI, Chad; RUI YANG et al.Clinical cancer research. 2007, Vol 13, Num 20, pp 6136-6143, issn 1078-0432, 8 p.Article

StI571 as a targeted therapy for CMLO'DWYER, Michael E; MAURO, Michael J; DRUKER, Brian J et al.Cancer investigation. 2003, Vol 21, Num 3, pp 429-438, issn 0735-7907, 10 p.Article

STI571: A paradigm of new agents for cancer therapeuticsMAURO, Michael J; O'DWYER, Michael; HEINRICH, Michael C et al.Journal of clinical oncology. 2002, Vol 20, Num 1, pp 325-334, issn 0732-183XArticle